Axoft
A neurotechnology company developing implantable Brain-Computer Interfaces.
About
Axoft is a neurotechnology company focused on developing implantable Brain-Computer Interfaces (BCIs). The company aims to advance the treatment of neurological disorders and enhance human capabilities through its innovative technology. Axoft has raised significant funding to expand its clinical trials globally and pursue U.S.
Similar companies
Developing ultra-high bandwidth brain-machine interfaces to connect humans and computers.
Shares Neurotechnology, Medical Devices
Developing a cortical visual prosthesis to restore functional vision for the severely blind.
Shares Neurotechnology, Medical Devices
Developing non-invasive ultrasound technology to treat age-related brain diseases like Alzheimer's.
Shares Neurotechnology, Medical Devices
NeuroTech company developing therapies to restore movement and independence for people with spinal cord injuries.
Shares Biotechnology, Medical Devices
Developing soft, stretchable brain-computer interface platforms.
Shares Biotechnology, Medical Devices
Digital pathology imaging technology and AI-driven precision pathology software.
Shares Biotechnology, Artificial Intelligence
Key facts
- Headquarters
- Cambridge, Massachusetts, USA
- Total funding
- $55M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 29 Apr 2026 | Series A | $55M | C.P. Group Innovation |
Frequently asked
What does Axoft do?
regulatory approval for its BCI technology.
How much funding has Axoft raised?
Axoft has raised a total of $55M in funding. The most recent round on record is Series A.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Axoft
